<DOC>
	<DOCNO>NCT03092895</DOCNO>
	<brief_summary>This open-label，Non-Randominzed Phase 2 study evaluate Safety Tolerability SHR-1210 combination Apatinib FOLFOX4 regimen subject Advanced PLC . Participants advance PLC fail intolerable prior systemic therapy treat SHR-1210 plus Apatinib ; Participants advance PLC never receive prior systemic therapy treat SHR-1210 plus FOLFOX4 regimen .</brief_summary>
	<brief_title>A Study SHR-1210 Combination With Apatinib FOLFOX4 Regimen Subjects With Advanced Primary Liver Cancer（PLC）</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm PLC advance stage ; suitable surgery local regional treatment ; least one measurable lesion per RECIST 1.1 . 2 . Arm A : Failed intolerable least one prior systemic treatment advance PLC . Arm B : No previous systemic treatment advance PLC . 3 . ECOG Performance Status 0 or1 . 4 . ChildPugh Class A B 7 point . 5 . Life Expectancy least 12 week . 6 . Has control infection Hepatitis B Virus ( HBV DNA＜500 IU/ml ) Hepatitis C Virus . 7 . Adequate organ function . 8 . Male female participant childbearing potential must willing use adequate method contraception start first dose study drug 60 day female subject 120 day male subject last dose study drug . 9 . Patient give write informed consent . 1 . Known fibrolamellar HCC ; Prior malignancy active previous 5 year except locally curable cancer apparently cure . 2 . Known occurrence central nervous system ( CNS ) metastases . 3 . Ascites clinical symptom . 4 . Known evidence GI hemorrhage within past 6 month . 5 . Known occurrence hemorrhage/ thrombus . 6 . Known evidence abdomen fistula , gastrointestinal perforation , abdominal abscess within past 2 month . 7 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia . 8 . Grade III~IV cardiac insufficiency , accord NYHA criterion echocardiography check : LVEF &lt; 50 % . 9 . Hypertension unable control within normal level follow treatment antihypertension agent ( systolic blood pressure &gt; 140mmHg , diastolic blood pressure &gt; 90 mmHg ) . 10 . Factors affect oral administration ( patient unable swallow oral medication , chronic diarrhea ileus etc . situation evidently affect drug oral medication absorption ) . 11 . History hepatic encephalopathy . 12 . Known history human immunodeficiency virus ( HIV ) infection . 13 . Active infection unexplained fever &gt; 38.5°C screen visit . 14 . Has receive live vaccine within 30 day . 15 . Prior plan organ transplantation include liver transplantation . 16 . Interstitial lung disease symptomatic may interfere detection management suspect drugrelated pulmonary toxicity . 17 . Proteinuria≥ 2+ 24 hour total urine protein &gt; 1.0 g. 18 . Active know , suspect autoimmune disease . 19 . Subjects condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day first administration study treatment . Inhaled topical steroid , adrenal replacement steroid dose &gt; 10 mg daily . prednisone equivalent , permit absence active autoimmune disease 20 . Any locoregional therapy liver ( include limit : resection , radiotherapy , TAE , TACE , TAI , RFA PEI ) within 4 week prior study . 21 . Prior therapy antiPD1 antiPD1/antiPDL1 immunotherapy . 22 . Known history hypersensitivity monoclonal antibody component study drug . 23 . Treatment anticoagulation therapy ( Warfarin heparin ) antiplatelet therapy ( aspirin dose≥300mg/day , clopidogrel dose≥75mg/day ) . 24 . Pregnant breastfeed woman . 25 . According investigator , condition may lead stop research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>